Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study

التفاصيل البيبلوغرافية
العنوان: Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study
المؤلفون: Ru‐Yu Lien, Heng‐Hsin Tung, Shang‐Laing Wu, Sophia H. Hu, Ling‐Chun Lu, Shu‐Fen Lu
المصدر: Cancer reports (Hoboken, N.J.). 5(7)
سنة النشر: 2021
مصطلحات موضوعية: Niacinamide, Cancer Research, Carcinoma, Hepatocellular, Oncology, Phenylurea Compounds, Liver Neoplasms, Quality of Life, Humans, Urea, Antineoplastic Agents, Hand-Foot Syndrome, Sorafenib
الوصف: Hand-foot skin reaction may influence the effectiveness of patients' treatment, patient quality of life, and the economics of health care. An effective prophylactic dermatological cream for preventing sorafenib-induced hand-foot skin reaction (HFSR) is yet to be identified.The aim of this study is validated the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma.This was a randomised double-blind experimental study. A total of 129 patients with advanced HCC were randomly assigned to three groups. The comparison group received best supportive care (BSC), group A received BSC plus a moisturising cream, and group B received BSC plus a 10% urea-based cream. Incidence of HFSR and cutaneous wetness were assessed 3 days before starting sorafenib and each week after starting sorafenib for 8 weeks.No significant difference was observed in the incidence density of sorafenib-induced HFSK (comparison group/A group, p .05; comparison group/B group, p .05). Group B reported significantly better cutaneous wetness of hands in the seventh week after starting sorafenib (p .05) and of feet during the first 6 weeks (p .05-.001).This study found a nut size amount of a 10% urea-based cream applied twice a day can maintain patients' cutaneous wetness in the first 6 weeks after starting sorafenib than moisturising-alone cream. But it cannot reduce the occurrence of HFSR. Thus, the result supports nut-size dose of the 10% urea-based cream three times a day may be an appropriate dose to prevent HFSR. Clinical Trail Registration Number: NCT04568330.
تدمد: 2573-8348
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceeab5d03d174d7f82b7f23a4319bd94
https://pubmed.ncbi.nlm.nih.gov/34910380
Rights: OPEN
رقم الانضمام: edsair.doi.dedup.....ceeab5d03d174d7f82b7f23a4319bd94
قاعدة البيانات: OpenAIRE